Karyopharm Therapeutics Inc. (KPTI)

Nasdaq: KPTI · Pharmaceutical Preparations · Newton, MA · filing with the SEC since 2010

Full chart Alerts Compare

Grade3.8

◀ Past 3.7● Present 3.6▶ Future 4.3

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$146M+0.6%

Net income-$196M-156.5%

Earnings per share$-17.93-28.1%

Operating cash flow-$75.4M+40.9%

Cash$60.5M-3.1%

Debtn/a

Shareholders’ equity-$293M-57.5%

Shares, diluted10.9M+29.3%

Return on equityn/a

The recordfrom its filings

Filings in 202694

Newest filingNov 12 · SCHEDULE 13G/A

Annual reportFeb 13, 2026

Quarterly reportAug 13, 2026

Next report due10-Q by Nov 14

Insider sales, 12 months$400,000

Insider buys, 12 months$0.00

Patents granted39

Filer categoryNon-accelerated filer<br>Smaller reporting company

Trailing twelve months to Jun 2026Revenue $147MNet income -$225MCash from operations -$65.3Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Nov 9, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Nov 2, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 28, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Oct 22, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 19, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Oct 14, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 8, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Karyopharm Therapeutics Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Newton, MA. Product was 79% of fiscal 2025 revenue.

Newest on the record

Large holder update, amended on Nov 12. Before it, large holder update, amended on Nov 9.

What is due next

The 10-Q for the period to Sep 30, 2026, due by Nov 14, 2026.

About KPTI

Karyopharm Therapeutics Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Newton, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $146 million and a loss of $196 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersNewton, MA

Business modelProduct business

ExchangeNasdaq

Filing since2010

Fiscal year endsDec 31

SEC number (CIK)1503802

Peers on fileCELU, AYTU, DERM, ETON

Who runs it

Financial performance

In fiscal 2025 Karyopharm Therapeutics’s revenue was $146.1 million, up 0.6% from $145.2 million the year before. It made a net loss of $196.0 million.

Annual report, filed Feb 13, 2026.

Financial statements

The grade

Karyopharm Therapeutics grades 3.8 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Eight of the nine metrics are read as filed and one is an SI estimate, each with its reasoning.

◀ Past3.7

● Present3.6

▶ Future4.3

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton KPTI · research, not advice